| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgeNCT05871970 | Protara Therapeutics | Phase 2 | Recruiting | 2026-12Estimated |
| Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesNCT05875701 | Novavax | Phase 3 | Completed | 2023-11-11Actual |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabNCT05877963 | TGTX | Phase 3 | Recruiting | 2027-01-21Estimated |
| HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLPNCT05883748 | IRON | Phase 2, Phase 3 | Enrolling by invitation | 2028-06Estimated |
| ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)NCT05889273 | MapLight Therapeutics | Phase 2 | Active not recruiting | 2027-11Estimated |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)NCT05892614 | ATYR | Phase 2 | Recruiting | 2026-04Estimated |
| Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).NCT05893537 | Cognition Therapeutics | Phase 2 | Terminated | 2025-03-04Actual |
| Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye DiseaseNCT05896670 | Oculis | Phase 2 | Completed | 2024-03-27Actual |
| A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett SyndromeNCT05898620 | NGNE | Phase 3 | Active not recruiting | 2029-12Estimated |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 | Summit Therapeutics | Phase 3 | Active not recruiting | 2028-12-31Estimated |
| Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT05903924 | Vanda Pharmaceuticals | Phase 3 | Completed | 2024-04-06Actual |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCVNCT05904470 | AVIR | Phase 2 | Completed | 2024-12-09Actual |
| Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-CNCT05905926 | Ardelyx | Phase 3 | Enrolling by invitation | 2031-07Estimated |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaNCT05907954 | IDEAYA Biosciences | Phase 2 | Active not recruiting | 2027-04-30Estimated |
| To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084 | HUMA | Phase 3 | Active not recruiting | 2027-06Estimated |
| Study of ALTO-300 in MDDNCT05922878 | Alto Neuroscience | Phase 2 | Recruiting | 2026-12Estimated |
| Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS VaccinesNCT05925127 | Novavax | Phase 2, Phase 3 | Completed | 2024-05-21Actual |
| A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late XerostomiaNCT05926765 | MeiraGTx, LLC | Phase 2 | Active not recruiting | 2027-06Estimated |
| 4D-150 in Patients With Diabetic Macular EdemaNCT05930561 | 4D Molecular Therapeutics | Phase 2 | Active not recruiting | 2029-02-28Estimated |
| A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODNCT05933200 | RARE | Phase 3 | Active not recruiting | 2027-08Estimated |
| Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.NCT05933525 | IMRN | Phase 2 | Completed | 2024-07-01Actual |
| This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).NCT05935085 | ANAB | Phase 2 | Terminated | 2024-10-16Actual |
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid ArthritisNCT05942911 | Incannex Healthcare Ltd | Phase 2 | Terminated | 2024-10-28Actual |
| Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic AtrophyNCT05949593 | BLTE | Phase 3 | Active not recruiting | 2027-06-30Estimated |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerNCT05951179 | Protara Therapeutics | Phase 2 | Recruiting | 2031-10Estimated |
| POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUNCT05953688 | ALMS | Phase 2 | Terminated | 2024-08-13Actual |
| Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerNCT05954143 | BOLT | Phase 2 | Terminated | 2024-09-20Actual |
| A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626 | Ocugen | Phase 2, Phase 3 | Active not recruiting | 2026-09-28Estimated |
| Refractory Chronic Cough Improvement Via NAL ER (RIVER)NCT05962151 | Trevi Therapeutics | Phase 2 | Completed | 2025-01-06Actual |
| Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus NephritisNCT05962788 | AUPH | Phase 3 | Terminated | 2025-07-04Actual |
Trial details
- Registry ID
- NCT05871970
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05875701
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05877963
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05883748
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05889273
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05892614
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05893537
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05896670
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05898620
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05899608
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05903924
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05904470
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05905926
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05907954
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05908084
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05922878
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05925127
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05926765
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05930561
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05933200
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05933525
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05935085
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05942911
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05949593
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05951179
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05953688
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05954143
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05956626
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05962151
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05962788
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.